BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28083618)

  • 21. [Association of CRBN Gene with Immunomodulatory Drug Resis- tance in Multiple Myeloma].
    Cai QQ; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):892-7. PubMed ID: 26117057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
    Lopez-Girona A; Heintel D; Zhang LH; Mendy D; Gaidarova S; Brady H; Bartlett JB; Schafer PH; Schreder M; Bolomsky A; Hilgarth B; Zojer N; Gisslinger H; Ludwig H; Daniel T; Jäger U; Chopra R
    Br J Haematol; 2011 Aug; 154(3):325-36. PubMed ID: 21707574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular mechanism of thalidomide analogs in hematologic malignancies.
    Lindner S; Krönke J
    J Mol Med (Berl); 2016 Dec; 94(12):1327-1334. PubMed ID: 27492707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IMiDs: Not for the CRBN weak.
    Pearse RN
    Leuk Res; 2014 Jan; 38(1):21-2. PubMed ID: 24239176
    [No Abstract]   [Full Text] [Related]  

  • 27. [Cereblon -  a new target of therapy in the treatment of multiple myeloma].
    Staňková M; Bešše L; Sedlaříková L; Vrábel D; Hájek R; Sevčíková S
    Klin Onkol; 2014; 27(5):326-30. PubMed ID: 25312709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of interferon regulatory factor 4 gene polymorphisms rs12203592 and rs872071 with skin cancer and haematological malignancies susceptibility: a meta-analysis of 19 case-control studies.
    Wang S; Yan Q; Chen P; Zhao P; Gu A
    BMC Cancer; 2014 Jun; 14():410. PubMed ID: 24906573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advances of CRBN in Immunomodulatory Drugs for Multiple Myeloma-Review].
    An R; Hou J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1888-1891. PubMed ID: 28024514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
    Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
    Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IRF4 rs12203592 functional variant and melanoma survival.
    Potrony M; Rebollo-Morell A; Giménez-Xavier P; Zimmer L; Puig-Butille JA; Tell-Marti G; Sucker A; Badenas C; Carrera C; Malvehy J; Schadendorf D; Puig S
    Int J Cancer; 2017 Apr; 140(8):1845-1849. PubMed ID: 28103633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
    Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
    Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Wróbel T; Butrym A; Łacina P; Rybka J; Gębura K; Mazur G; Bogunia-Kubik K
    Anticancer Res; 2017 Apr; 37(4):1799-1803. PubMed ID: 28373444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
    Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
    Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma.
    Gathany AH; Hartge P; Davis S; Cerhan JR; Severson RK; Cozen W; Rothman N; Chanock SJ; Wang SS
    Cancer Causes Control; 2009 Oct; 20(8):1291-302. PubMed ID: 19396635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression.
    Li N; Johnson DC; Weinhold N; Studd JB; Orlando G; Mirabella F; Mitchell JS; Meissner T; Kaiser M; Goldschmidt H; Hemminki K; Morgan GJ; Houlston RS
    Nat Commun; 2016 Nov; 7():13656. PubMed ID: 27882933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma.
    Pratt G; Fenton JA; Allsup D; Fegan C; Morgan GJ; Jackson G; Sunter NJ; Hall AG; Irving JA; Allan JM
    Br J Haematol; 2010 Aug; 150(3):371-3. PubMed ID: 20408839
    [No Abstract]   [Full Text] [Related]  

  • 40. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.